Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction

Müller, Julian; Ferraro, Daniela A.; Muehlematter, Urs J.; Garcia Schüler, Helena I.; Kedzia, Sarah; Eberli, Daniel; Guckenberger, Matthias; Kroeze, Stephanie G. C.; Sulser, Tullio; Schmid, Daniel M.; Omlin, Aurelius; Müller, Alexander; Zilli, Thomas; John, Hubert; Kranzbuehler, Helmut; Kaufmann, Philipp A.; von Schulthess, Gustav K.; Burger, Irene A.

doi:10.1007/s00259-018-4203-0

Scientific article

English

Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction

ContributorsMüller, Julian; Ferraro, Daniela A.; Muehlematter, Urs J.; Garcia Schüler, Helena I.; Kedzia, Sarah; Eberli, Daniel; Guckenberger, Matthias; Kroeze, Stephanie G. C.; Sulser, Tullio; Schmid, Daniel M.; Omlin, Aurelius; Müller, Alexander; Zilli, Thomas; John, Hubert; Kranzbuehler, Helmut; Kaufmann, Philipp A.; von Schulthess, Gustav K.; Burger, Irene A.

Published inEuropean Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 4, p. 889-900

Publication date2019

Abstract

The fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts. Since the superiority of 68Ga-PSMA-11 PET in detecting recurrent PCA is well established, the aim of our study was to assess its effect on management and outcome in all patients imaged during the first year after its introduction into clinical routine.

Keywords

PSMA
Detection rate
Prostate cancer
Biochemical recurrence
Change in management
Targeted

Affiliation

Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale

Research group

Laboratoire de radiothérapie de haute précision pour le cancer de la prostate (1014)

Citation (ISO format)

MÜLLER, Julian et al. Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. In: European Journal of Nuclear Medicine and Molecular Imaging, 2019, vol. 46, n° 4, p. 889–900. doi: 10.1007/s00259-018-4203-0

Article (Published version)

Identifiers

PID : unige:136208
DOI : 10.1007/s00259-018-4203-0
PMID : 30488099

Commercial URLhttp://link.springer.com/10.1007/s00259-018-4203-0

ISSN of the journal1619-7070

214views

0downloads

Creation04/28/2020 4:54:00 PM

First validation04/28/2020 4:54:00 PM

Update time03/15/2023 9:58:34 PM

Status update03/15/2023 9:58:33 PM

Last indexation01/17/2024 9:53:51 AM

Archive ouverte UNIGE

Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction

Technical informations